日报更新时间:
周报更新时间:04-11 03:39
今开价:123.67
最高价:128.35
成交量:581998.0
昨收价:123.2
最低价:122.34
最新价:127.3
中文名称:窥得儿医药
英文名称:Quidel
行业:医疗
简介:Quidel Corporation是一家成立于特拉华州的企业
电话:1-858-5521100
交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
---|---|---|---|---|---|
2019-06-27 | Bryant (Douglas C) | Chief Executive Officer | Sell | 3461 | 60.06 |
2019-06-27 | Bryant (Douglas C) | Chief Executive Officer | Buy | 3461 | 15.19 |
2019-06-25 | Bryant (Douglas C) | Chief Executive Officer | Buy | 19412 | 15.19 |
2019-06-25 | Bryant (Douglas C) | Chief Executive Officer | Buy | 5838 | 12.63 |
2019-06-25 | Bryant (Douglas C) | Chief Executive Officer | Sell | 25250 | 57.25 |
2019-06-17 | Russell (Edward Keith) | Officer | Buy | 4197 | 15.40 |
2019-06-17 | Russell (Edward Keith) | Officer | Buy | 8803 | 18.32 |
2019-06-17 | Russell (Edward Keith) | Officer | Sell | 13000 | 57.16 |
2019-05-26 | Kroll Werner | Officer | Buy | 4377 | -- |
2019-05-26 | Kroll Werner | Officer | Sell | 2170 | 54.42 |
2019-05-19 | Slacik (Charles P) | Director | Sell | 1000 | 55.19 |
2019-05-15 | Buechler (Kenneth F) | Director | Buy | 745 | -- |
2019-05-15 | Slacik (Charles P) | Director | Buy | 222 | -- |
2019-05-14 | Slacik (Charles P) | Director | Buy | 1661 | -- |
2019-05-14 | Schuler (Jack W) | Director and Beneficial Owner | Buy | 1661 | -- |
2019-05-14 | Strobeck (Matthew W) | Director | Buy | 1661 | -- |
2019-05-14 | Polan (Mary Lake Ph.D) | Director | Buy | 1661 | -- |
2019-05-14 | Michael (Edward L) | Director | Buy | 834 | -- |
2019-05-14 | Buechler (Kenneth F) | Director | Buy | 1919 | -- |
2019-05-14 | Widder Kenneth Jon | Director | Buy | 1661 | -- |
2019-05-09 | Buechler (Kenneth F) | Director | Sell | 2002 | 60.58 |
2019-05-09 | Buechler (Kenneth F) | Director | Buy | 2002 | 11.96 |
2019-05-04 | Polan (Mary Lake Ph.D) | Director | Buy | 1756 | -- |
2019-05-04 | Polan (Mary Lake Ph.D) | Director | Buy | 526 | -- |
2019-04-15 | Polan (Mary Lake Ph.D) | Director | Buy | 7800 | 15.73 |
机构持股 | |||||
---|---|---|---|---|---|
持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
Dimensional Fund Advisors LP | 604846 | 1.52% | -- | -- | 2019-07-31 |
Fred Alger Management Inc | 1067910 | 2.68% | -19482 | -1.79% | 2019-03-31 |
ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 1138948 | 2.86% | -194099 | -14.56% | 2019-03-31 |
BlackRock Fund Advisors | 1161341 | 2.92% | 5742 | 0.50% | 2019-07-31 |
Oracle Investment Management Inc | 1903558 | 4.78% | -- | -- | 2019-03-31 |
BlackRock Inc | 2288226 | 5.75% | -16268 | -0.71% | 2019-03-31 |
Vanguard Group Inc | 3201751 | 8.04% | 162461 | 5.35% | 2019-03-31 |
Brown Capital Management, LLC | 5467982 | 13.73% | -72242 | -1.30% | 2019-03-31 |
T. Rowe Price Associates, Inc. | 6672209 | 16.76% | 17373 | 0.26% | 2019-03-31 |
Macquarie Group Ltd | 1004395 | 2.52% | 52544 | 5.52% | 2019-03-31 |
Vanguard Investments Australia Ltd | 940225 | 2.36% | 11688 | 1.26% | 2019-07-31 |
State Street Corporation | 860895 | 2.16% | 45931 | 5.64% | 2019-03-31 |
Marshall Wace Asset Management Ltd | 623440 | 1.57% | 247006 | 65.62% | 2019-03-31 |
Eagle Asset Management, Inc. | 639841 | 1.61% | 8939 | 1.42% | 2019-03-31 |
Northern Trust Investments Inc | 684176 | 1.72% | 10087 | 1.50% | 2019-07-31 |
T. Rowe Price | 728906 | 1.83% | 8680 | 1.21% | 2019-07-31 |
Dimensional Fund Advisors, Inc. | 749233 | 1.88% | -111926 | -13.00% | 2019-03-31 |
New York State Common Retirement Fund | 749998 | 1.88% | 1700 | 0.23% | 2019-03-31 |
Macquarie Investment Management | 838805 | 2.11% | 63240 | 8.15% | 2019-07-31 |
Delaware Management Company | 840485 | 2.11% | 23212 | 2.84% | 2019-07-31 |
BlackRock Asset Management Canada Ltd | 796401 | 2.00% | -114 | -0.01% | 2019-05-31 |
Geode Capital Management, LLC | 775754 | 1.95% | 415831 | 115.53% | 2018-12-31 |
Gabelli Funds LLC | 613000 | 1.55% | -- | -- | 2018-12-31 |
FMG LLC | 468099 | 1.19% | 300 | 0.06% | 2019-03-31 |
Gamco Investors, Inc. Et Al | 505700 | 1.28% | -2000 | -0.39% | 2018-12-31 |
OFI Global Asset Management, Inc. | 732619 | 1.86% | 44484 | 6.46% | 2018-12-31 |
OppenheimerFunds Inc | 901814 | 2.29% | -204 | -0.02% | 2018-09-30 |
Delaware Management Business Trust | 830139 | 2.11% | -272476 | -24.71% | 2018-06-30 |
BlackRock Institutional Trust Company NA | 918266 | 2.33% | 109093 | 13.48% | 2018-06-30 |
Millennium Management LLC | 555948 | 1.41% | -440867 | -44.23% | 2018-06-30 |
State Street Corp | 726889 | 1.86% | 90126 | 14.15% | 2018-06-30 |
Renaissance Technologies Corp | 507687 | 1.30% | -66413 | -11.57% | 2018-06-30 |
Northern Trust Investments N A | 424383 | 1.09% | 57813 | 15.77% | 2018-06-30 |
D. E. Shaw & Co LP | 394586 | 1.01% | -23477 | -5.62% | 2018-06-30 |
Cannell Peter B & CO Inc | 354800 | 0.91% | -500 | -0.14% | 2018-06-30 |
Rothschild Asset Management Inc | 382565 | 0.98% | 382565 | -- | 2018-06-30 |
MFS Investment Management KK | 333652 | 0.86% | 60651 | 22.22% | 2018-06-30 |
Goldman Sachs Asset Management LP | 790776 | 2.11% | -14561 | -1.81% | 2018-03-31 |
Point72 Asset Management, L.P. | 636764 | 1.70% | 370763 | 139.38% | 2018-03-31 |
NORGES BANK | 573538 | 1.66% | -203168 | -26.16% | 2017-12-31 |
Marshall Wace North America LP | 474884 | 1.40% | 303084 | 176.42% | 2017-09-30 |
Macquarie Investment Management Limited | 1004662 | 2.96% | 1004662 | -- | 2017-09-30 |
Wellington Management Company LLP | 390323 | 1.15% | 390323 | -- | 2017-09-30 |
Test Hedge Fund Mgmt | 397770 | 1.17% | 397770 | -- | 2017-09-30 |
Janus Capital Management LLC | 2073696 | 6.30% | -743998 | -26.40% | 2016-12-31 |
J.P. Morgan Investment Management Inc | 593850 | 1.82% | -217000 | -26.76% | 2016-09-30 |
Arrowpoint Asset Management, LLC | 1093455 | 3.35% | -194095 | -15.07% | 2016-09-30 |
Vanguard Group | 1796645 | 3.00% | 44682561 | -- | 1999-11-30 |
Entities affiliated with Larry N. Feinberg | 2911133 | 3.00% | 72399878 | 0.10% | 1999-11-30 |
Wellington Management Group, LLP | 3244157 | 3.00% | 80682185 | 0.10% | 1999-11-30 |
Jack W. Schuler | 5339671 | 3.00% | 132797618 | 0.20% | 1999-11-30 |
共同基金持股 | |||||
---|---|---|---|---|---|
持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
iShares Russell 2000 Growth ETF | 324973 | 0.82% | 4109 | 1.28% | 2019-07-30 |
Delaware Sm-Cap Core Eq-UBS | 838805 | 2.11% | 63240 | 8.15% | 2019-06-30 |
T. Rowe Price Health Sciences Fund | 849533 | 2.13% | -5500 | -0.64% | 2019-06-30 |
Vanguard Small Cap Index | 912749 | 2.29% | 37534 | 4.29% | 2019-06-30 |
Vanguard Total Stock Market Index Fund | 931567 | 2.34% | 10389 | 1.13% | 2019-06-30 |
T. Rowe Price Small-Cap Stock Fund | 993500 | 2.50% | -6300 | -0.63% | 2019-06-30 |
T. Rowe Price New Horizons Fund | 1033468 | 2.60% | -3300 | -0.32% | 2019-06-30 |
T. Rowe Price Small-Cap Value Fund | 1461606 | 3.67% | -107000 | -6.82% | 2019-06-30 |
Brown Capital Management Small CompanyFd | 2835704 | 7.12% | 143497 | 5.33% | 2019-06-30 |
Delaware Small Cap Core Fund | 838805 | 2.11% | 23322 | 2.86% | 2019-06-30 |
Alger Small Cap Focus Fund | 836020 | 2.10% | 210137 | 33.57% | 2019-05-31 |
iShares Russell 2000 ETF | 772606 | 1.94% | 1507 | 0.20% | 2019-07-30 |
T. Rowe Price U.S. Small-Cap Value Eq Tr | 351082 | 0.88% | -11400 | -3.14% | 2019-06-30 |
Carillon Eagle Small Cap Growth Fund | 397803 | 1.00% | -- | -- | 2019-06-30 |
1290 VT GAMCO Small Company Value Port | 446000 | 1.12% | -- | -- | 2019-05-31 |
Vanguard Extended Market Index Fund | 489530 | 1.23% | 772 | 0.16% | 2019-06-30 |
Gabelli Small Cap Growth Fund | 505000 | 1.27% | -69000 | -12.02% | 2019-03-31 |
Vanguard Small Cap Growth Index Fund | 524853 | 1.32% | 28200 | 5.68% | 2019-06-30 |
T. Rowe Price US SmCp Core Equity Tr | 527486 | 1.32% | 15000 | 2.93% | 2019-06-30 |
T. Rowe Price Instl Small-Cap Stock Fund | 527486 | 1.32% | 15000 | 2.93% | 2019-06-30 |
DFA US Small Cap Portfolio | 282609 | 0.71% | -- | -- | 2019-04-30 |
iShares US Small Cap ETF (CAD-Hedged) | 696747 | 1.75% | -1170 | -0.17% | 2019-05-30 |
Vanguard Small Cap Index Fund | 876420 | 2.20% | 6142 | 0.71% | 2019-04-30 |
Vanguard Explorer Fund | 282636 | 0.71% | 282636 | -- | 2018-12-31 |
Meridian Growth Fund | 259457 | 0.65% | 259457 | -- | 2018-12-31 |
Columbia Small Cap Growth Fund I | 242900 | 0.62% | 26100 | 12.04% | 2019-02-28 |
T. Rowe Price US Smaller Companies Eq Fd | 239265 | 0.61% | 4105 | 1.75% | 2018-12-31 |
Nationwide Small Company Growth Fund | 191341 | 0.49% | -- | -- | 2018-12-31 |
MFS New Discovery Fund | 228073 | 0.58% | 28127 | 14.07% | 2018-11-30 |
Oppenheimer Discovery Fund | 469740 | 1.19% | 40660 | 9.48% | 2018-11-30 |
Goldman Sachs Small Cap Value Fund | 512946 | 1.30% | -12251 | -2.33% | 2018-03-31 |
MFS | 199946 | 0.51% | -- | -- | 2018-10-31 |
Alger Small Cap Focus A | 648582 | 1.66% | 34865 | 5.68% | 2018-06-30 |
DFA US Micro Cap I | 182774 | 0.47% | -13600 | -6.93% | 2018-07-31 |
SPDR | 171589 | 0.42% | 998 | 0.59% | 2018-09-13 |
Nationwide Small Company Growth A | 191341 | 0.49% | -- | -- | 2018-07-31 |
MFS New Discovery A | 199946 | 0.51% | -- | -- | 2018-07-31 |
DFA US Small Cap I | 252545 | 0.65% | -- | -- | 2018-07-31 |
Brown Capital Mgmt Small Co Inv | 2521626 | 6.47% | 1224 | 0.05% | 2018-06-30 |
T. Rowe Price Small-Cap Value | 1681000 | 4.31% | -11000 | -0.65% | 2018-06-30 |
T. Rowe Price Health Sciences | 913533 | 2.34% | 115600 | 14.49% | 2018-06-30 |
T. Rowe Price Small-Cap Stock | 911900 | 2.34% | 911900 | -- | 2018-06-30 |
Vanguard Total Stock Mkt Idx | 799818 | 2.05% | 920 | 0.12% | 2018-07-31 |
Delaware Small Cap Core A | 622000 | 1.59% | 18900 | 3.13% | 2018-07-31 |
Gabelli Small Cap Growth AAA | 578000 | 1.48% | -12000 | -2.03% | 2018-06-30 |
EQ/GAMCO Small Company Value IB | 460000 | 1.18% | -25000 | -5.15% | 2018-07-31 |
iShares Russell 2000 Growth | 317236 | 0.77% | -306 | -0.10% | 2018-09-12 |
Vanguard Extended Market Idx Inv | 426900 | 1.09% | 3200 | 0.76% | 2018-07-31 |
T. Rowe Price Instl Small-Cap Stock | 439800 | 1.13% | 439800 | -- | 2018-06-30 |
Oppenheimer Discovery A | 432540 | 1.11% | 33060 | 8.28% | 2018-07-31 |
Vanguard Small Cap Growth Index Inv | 457415 | 1.17% | 6813 | 1.51% | 2018-07-31 |
Oppenheimer Main Street Small Cap VA Svc | 181270 | 0.46% | -33610 | -15.64% | 2018-07-31 |
Fidelity Spartan | 142157 | 0.38% | 13550 | 10.54% | 2018-05-31 |
Goldman Sachs Small Cap Value A | 512946 | 1.37% | -12251 | -2.33% | 2018-03-31 |
Alger Small Cap Growth Institutional I | 151885 | 0.41% | -2177 | -1.41% | 2018-04-30 |
Alger Small Cap Growth I-2 | 156425 | 0.42% | -2084 | -1.31% | 2018-03-31 |
Northwestern Mutual Ser Small Cap Value | 138800 | 0.37% | -4300 | -3.00% | 2018-03-31 |
Loomis Sayles Small Cap Value Instl | 139565 | 0.40% | -- | -- | 2018-01-31 |
TETON Westwood Mighty Mites AAA | 147061 | 0.43% | -- | -- | 2017-12-31 |
Janus Triton D | 1317098 | 4.03% | -20605 | -1.54% | 2016-12-31 |
Janus Venture D | 506048 | 1.55% | -143201 | -22.06% | 2016-12-31 |
Meridian Growth Legacy | 298579 | 0.91% | -- | -- | 2016-12-31 |
Vanguard Explorer Inv | 278908 | 0.85% | -62647 | -18.34% | 2016-09-30 |
JPMorgan US Small Company Instl | 284200 | 0.87% | 7000 | 2.53% | 2016-12-31 |
JPMorgan Small Cap Value A | 188000 | 0.58% | -- | -- | 2016-12-31 |
Janus Triton Fund | 1706087 | 5.10% | -- | -- | 2015-09-30 |
Janus Venture Fund | 714395 | 2.10% | -- | -- | 2015-09-30 |
EQ/GAMCO Small Company Value | 548000 | 1.60% | -- | -- | 2015-09-30 |
iShares Russell 2000 (AU) | 458601 | 1.50% | -576 | -0.10% | 2015-11-19 |
Meridian Growth Fund® | 416478 | 1.20% | 27159 | 7.00% | 2015-09-30 |
Loomis Sayles Small Cap Growth Fund | 314772 | 0.90% | 572 | 0.20% | 2015-09-30 |
JPMorgan Small Cap Value | 314303 | 0.90% | 133503 | 73.80% | 2015-09-30 |
Brown Capital Management Small Company | 2508452 | 7.50% | -- | -- | 2015-10-31 |
Jack W. Schuler | Founder of Crabtree Partners LLC, Jack W. Schuler is on the board of Quidel Corp., Accelerate Diagnostics, Inc. and Biodesix, Inc. and Partner at Crabtree Partners LLC. In his past career Mr. Schuler held the position of Lead Independent Director at Stericycle, Inc., President & Chief Operating Officer for Abbott Laboratories and Chairman at Ventana Medical Systems, Inc. Mr. Schuler received an undergraduate degree from Tufts University and an MBA from Stanford Graduate School of Business. |
---|---|
Randall J. Steward | Presently, Randall J. Steward occupies the position of Chief Financial Officer of Quidel Corp. He is also Member of The American Institute of Certified Public Accountants. In the past Mr. Steward held the position of Chief Operating Officer at SeQual Technologies, Inc., Chief Financial Officer for Navilyst Medical, Inc., Chief Financial Officer & Executive Vice President of Spectrum Brands, Inc. and Independent Consultant at Thermoscan, Inc. Mr. Steward received an undergraduate degree from Southern Methodist University. |
Kenneth J. Widder | Founder of Santarus, Inc., Molecular Biosystems, Inc., FeRx, Inc. and NovaCardia, Inc., Kenneth J. Widder is an entrepreneur and businessperson who has been at the head of 6 different companies and currently holds the position of Executive Chairman for OrphoMed, Inc. and Partner at Latterell Venture Partners. Dr. Widder is also on the board of 7 other companies. In his past career he was Chairman & Chief Executive Officer of Converge Medical, Inc., Managing Member at Windamere Venture Partners LLC, Chairman & Chief Executive Officer at Molecular Biosystems, Inc., Chairman at Sytera, Inc., Chairman for Santarus, Inc. and Chief Executive Officer at NovaCardia, Inc. Dr. Widder received an undergraduate degree from Carleton College and a graduate degree from Northwestern University. |
Karen S. Gibson | Karen S. Gibson is VP, Information Services & Integration Lead at Quidel Corp. In her past career she occupied the position of Chief Information Officer & Senior Vice President of Invitrogen Corp., Chief Information Officer & Senior Vice President at US Oncology, Inc., Director-Information Technology at Accredo Health Group, Inc., Chief Information Officer & VP-Global eBusiness at GE Medical Systems Cesk�0�1�0�3 Republika sro, Chief Information Officer & Vice President at GE Healthcare IT, Chief Information Officer & Senior Vice President for McKesson Specialty Health, Inc., Chief Information Officer & Senior Vice President of Life Technologies, Inc. and Information Management Leader at General Electric Industrial Control Systems. She received an undergraduate degree from Purdue University and an MBA from The Ohio University. |
Thomas D. Brown | Thomas D. Brown is on the board of Quidel Corp., Accelerate Diagnostics, Inc. and Stericycle, Inc. Mr. Brown previously occupied the position of President-Diagnostics Division & Senior VP at Abbott Laboratories. Mr. Brown received an undergraduate degree from State University of New York at Buffalo. |
Werner Kroll | Currently, Werner Kroll occupies the position of Senior Vice President-Research & Development at Quidel Corp. Dr. Kroll is also on the board of European Personalised Medicine Association. In his past career Dr. Kroll was VP & Head-Research & Innovation at Novartis Institutes for Biomedical Research, Inc. He received a doctorate from Philipps University of Marburg. |
Michael Donald Abney | Michael Donald Abney is Senior Vice President-Distribution at Quidel Corp. In the past he occupied the position of Vice President-Supplier Management at PSS World Medical, Inc. and Vice President-Channel & Distribution at ConvaTec, Inc. Mr. Abney received an undergraduate degree from the University of Florida and an undergraduate degree from the University of Florida. |
Charles P. Slacik | Charles P. Slacik is on the board of Quidel Corp. and Member of Financial Executives International - Orange County and Member of The Connecticut Society of Certified Public Accountants. In the past Mr. Slacik held the position of Chief Financial Officer & Executive Vice President at Actavis, Inc., Chief Financial Officer & Senior Vice President at Beckman Coulter, Inc. and Chief Financial Officer & Senior Vice President of C.R. Bard, Inc. (New Jersey). Mr. Slacik received an undergraduate degree from the University of Connecticut. |
Kenneth F. Buechler | Founder of Alere San Diego, Inc. and Biosite, Inc. (Massachusetts), Kenneth F. Buechler presently is Chairman for Quidel Corp. He is also on the board of Sotera Wireless, Inc., Astute Medical, Inc. and Edico Genome Corp. and Member of American Association for Clinical Chemistry, Member of Biochemical Society, Member of International Federation of Clinical Chemistry & Lab Medicine and Member of American Chemical Society. Kenneth F. Buechler previously occupied the position of Chairman of Sequenom, Inc., President, Director & Chief Scientific Officer at Biosite, Inc. (Massachusetts), President & Chief Scientific Officer at Alere San Diego, Inc. and Senior Scientist at Hybritech, Inc. Kenneth F. Buechler received an undergraduate degree and a doctorate from Indiana University. |
Mary Lake Polan | Mary Lake Polan is Professor at Yale School of Medicine and Member of Institute of Medicine and on the board of 8 other companies. She previously occupied the position of Managing Director at Golden Seeds, Inc. and Professor at Stanford University School of Medicine. She received an undergraduate degree from Connecticut College, a graduate degree from the University of California, Berkeley, a doctorate from Yale School of Medicine and a doctorate from Yale University. |
Matthew William Strobeck | Founder of Birchview Capital LP, Matthew William Strobeck currently is Chief Investment Officer & Managing Partner at this company. Dr. Strobeck is also on the board of 6 other companies. In the past Dr. Strobeck was Consultant at Thomas Weisel Asset Management LLC and Partner at Westfield Capital Management Co. LP. He received a doctorate from the University of Cincinnati (Ohio), an undergraduate degree from St. Lawrence University, a graduate degree from Harvard University and a graduate degree from MIT Sloan School of Management. |
Douglas C. Bryant | Douglas C. Bryant holds the position of President, Chief Executive Officer & Director at Quidel Corp. Mr. Bryant previously was Chief Operating Officer & Executive Vice President of Luminex Corp. and VP-Molecular Global Commercial Operations at Abbott Laboratories Vice President-Asia & Japan at Abbott Vascular Devices and Vice President-Global Commercial Operations at Abbott Diagnostics, Inc. (both are subsidiaries of Abbott Laboratories). Douglas C. Bryant received an undergraduate degree from the University of California, Davis. |
Edward L. Michael | Edward L. Michael occupies the position of Executive Partner at Tyree & D'Angelo Partners LLC. He is also on the board of 6 other companies. He previously occupied the position of Executive Vice President-Diagnostics Products at Abbott Laboratories Senior Vice President-Medical Products at Abbott Molecular, Inc. and Vice President-Immunoassay & Clinical Chemistry at Abbott Diagnostics, Inc. (both are subsidiaries of Abbott Laboratories), Senior Vice President-Medical Products at Abbott Spine, Inc. and Senior Vice President-Medical Products at Abbott Animal Health, Inc. Mr. Michael received an undergraduate degree and a graduate degree from Indiana University. |
Kathy P. Ordo�0�1±ez | Kathy P. Ordo�0�1±ez is a businessperson who founded Celera Diagnostics LLC and who has been the head of 6 different companies. She is on the board of Quidel Corp., Pacific Biosciences of California, Inc. and Advanced Medical Technology Association. In the past Ms. Ordo�0�1±ez held the position of President of Celera Diagnostics LLC, Senior Vice President-Diagnostic Solutions at Quest Diagnostics, Inc. President & Chief Executive Officer at Celera Corp. and President of Celera Group (both are subsidiaries of Quest Diagnostics, Inc.), Non-Executive Chairman & Chief Executive Officer at RainDance Technologies, Inc., President & Chief Executive Officer for Roche Molecular Systems, Inc., President at Roche Diagnostics Corp., Principal at Hoffmann-La Roche, Inc. and Senior Vice President at Applera Corp. She received an MBA from Pace University and an undergraduate degree from Hartwick College. |
Robert Joseph Bujarski | Presently, Robert Joseph Bujarski occupies the position of Senior Vice President & General Counsel at Quidel Corp. He previously held the position of Associate Attorney at Gibson, Dunn & Crutcher LLP. He received an undergraduate degree and a graduate degree from the University of Arizona. |
William J. Ferenczy | William J. Ferenczy is Vice President Strategy at Quidel Corp. He previously held the position of Principal at General Medical Corp., Principal at Abbott Laboratories and Vice President-Marketing at Alere San Diego, Inc. (a subsidiary of Abbott Laboratories) and Vice President-Sales & Marketing of Inovise Medical, Inc. Mr. Ferenczy received an undergraduate degree from the University of Notre Dame. |
Ruben Argueta | Presently, Ruben Argueta occupies the position of Media & Investor Relations Contact at Quidel Corp. |
Edward Kieth Russell | Edward Kieth Russell is Senior Vice President-Global Commercial Operations at Quidel Corp. In his past career Mr. Russell occupied the position of President & General Manager at Life Technologies Japan Ltd. and General Manager-Global Services & Support Division at Life Technologies, Inc. Mr. Russell received an undergraduate degree from US Coast Guard Academy and an MBA from The Wharton School of the University of Pennsylvania. |
Ratan S. Borkar | Ratan S. Borkar is Senior VP-International Commercial Operations at Quidel Corp. Mr. Borkar received an MBA from Stephen M. Ross School of Business and an undergraduate degree from the University of Mumbai. |
Edward L. Michael | Edward L. Michael occupies the position of Executive Partner at Tyree & D'Angelo Partners LLC. He is also on the board of 6 other companies. He previously occupied the position of Executive Vice President-Diagnostics Products at Abbott Laboratories Senior Vice President-Medical Products at Abbott Molecular, Inc. and Vice President-Immunoassay & Clinical Chemistry at Abbott Diagnostics, Inc. (both are subsidiaries of Abbott Laboratories), Senior Vice President-Medical Products at Abbott Spine, Inc. and Senior Vice President-Medical Products at Abbott Animal Health, Inc. Mr. Michael received an undergraduate degree and a graduate degree from Indiana University. |
Phillip Askim | Presently, Phillip Askim holds the position of Secretary at Quidel Corp. |
热门推荐
全部评论 0
暂无评论